当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.

Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.

Abstract：

BACKGROUND:Neuraminidase (NA) inhibitors (NAIs), including oseltamivir and zanamivir, play an important therapeutic role against influenza infections in immunocompromised patients. In such settings, however, NAI therapy may lead to the emergence of resistance involving mutations within the influenza surface genes. The aim of this study was to investigate the evolution of NA and haemagglutinin (HA) genes of influenza A(H1N1)pdm09 virus in an immunocompromised patient receiving oseltamivir then zanamivir therapies. METHODS:Nasopharyngeal swab (NPS) samples were collected between 27 January 2018 and 11 April 2018 from a haematopoietic stem cell transplant recipient. These include 10 samples collected either pre-therapy, during oseltamivir and zanamivir treatment as well as after therapy. The A(H1N1)pdm09 HA/NA genes were sequenced. The H275Y NA substitution was quantified by droplet digital RT-PCR assay. A(H1N1)pdm09 recombinant viruses containing HA mutations were tested by HA elution experiments to investigate in vitro binding properties. RESULTS:Oseltamivir rapidly induced the H275Y NA mutation which constituted 98.33% of the viral population after 15 days of oseltamivir treatment. The related HA gene contained S135A and P183S substitutions within the receptor-binding site. After a switch to zanamivir, 275H/Y and 119E/G/D mixed populations were detected. In the last samples, the double H275Y-E119G NA variant dominated with S135A and P183S HA substitutions. CONCLUSIONS:This report confirms that oseltamivir can rapidly induce the emergence of the H275Y substitution in A(H1N1)pdm09 viruses and subsequent switch to zanamivir can lead to additional substitutions at codon E119 resulting in multi-drug resistance. Such data additionally suggest a potential compensatory role for HA substitutions near the receptor binding site.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Abed Y,Schibler M,Checkmahomed L,Carbonneau J,Venable MC,Fage C,Giannotti F,Goncalves AR,Kaiser L,Boivin G

doi

10.3851/IMP3344

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

581-587

issue

8

eissn

1359-6535

issn

2040-2058

journal_volume

24

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • Zidovudine treatment is not associated with HTLV-1 reverse transcriptase gene mutations in HTLV-I/HIV-1 co-infected patients.

    abstract：:Zidovudine treatment of human immunodeficiency virus (HIV) infection induces drug-resistant viral strains harbouring specific amino acid substitutions in the reverse transcriptase (RT). To investigate whether this phenomenon could be observed in the case of human T lymphotropic virus type I (HTLV-I) infection, we anal...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Gasmi M,Fillon S,Leriche K,Neisson-Vernant C,Desgranges C

    更新日期：1997-04-01 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract：BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期：2007-01-01 00:00:00

  • In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.

    abstract：:The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Kosmiski LA,Miller HL,Klemm DJ

    更新日期：2006-01-01 00:00:00

  • NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.

    abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2326

    authors： Maimone S,Musolino C,Squadrito G,Raffa G,Pollicino T,Raimondo G

    更新日期：2013-01-01 00:00:00

  • On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.

    abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2777

    authors： Huang YW,Takahashi S,Tsuge M,Chen CL,Wang TC,Abe H,Hu JT,Chen DS,Yang SS,Chayama K,Kao JH

    更新日期：2015-01-01 00:00:00

  • HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

    abstract：:The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2951

    authors： Marra CM

    更新日期：2015-01-01 00:00:00

  • Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

    abstract：:The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Matsumoto K,Ogawa N,Nerome K,Numazaki Y,Kawakami Y,Shirato K,Arakawa M,Kudoh S,Shimokata K,Nakajima S,Yamakido M,Kashiwagi S,Nagatake T

    更新日期：1999-01-01 00:00:00

  • Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.

    abstract：:A novel severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. We previously isolated and characterized SARS-CoV and SARS-CoV-like viruses from human and animals, respectively, suggesting that SARS could be transmitted from wild/farmed animals ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Zheng BJ,Guan Y,Hez ML,Sun H,Du L,Zheng Y,Wong KL,Chen H,Chen Y,Lu L,Tanner JA,Watt RM,Niccolai N,Bernini A,Spiga O,Woo PC,Kung HF,Yuen KY,Huang JD

    更新日期：2005-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • Effect of long-term lamivudine in chronic hepatitis B virus-infected children.

    abstract：OBJECTIVE:To evaluate, retrospectively, biochemical, serological and histological responses in chronic hepatitis B (CHB)-infected children who received combination therapy and continued with prolonged treatment with lamivudine (3TC). PATIENTS AND METHODS:CHB infection was defined as the presence of hepatitis B surface...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Ozgenç F,Arikan C,Sertoz RY,Nart D,Aydogdu S,Yagci RV

    更新日期：2004-10-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract：BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期：2008-01-01 00:00:00

  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期：2001-03-01 00:00:00

  • Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

    abstract：BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Parker S,Schriewer J,Oberle C,Robertson A,Lanier R,Painter G,Buller RM

    更新日期：2008-01-01 00:00:00

  • Preventing and treating secondary bacterial infections with antiviral agents.

    abstract：:Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1730

    authors： McCullers JA

    更新日期：2011-01-01 00:00:00

  • Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.

    abstract：BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Wiegand J,Cornberg M,Aslan N,Schlaphoff V,Sarrazin C,Kubitschke A,Buggisch P,Ciner A,Jaeckel E,Manns MP,Wedemeyer H

    更新日期：2007-01-01 00:00:00

  • Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.

    abstract：BACKGROUND:Hepatitis delta virus (HDV) infection therapy is unclear. This systematic analysis aimed to clarify the evidence on the efficacy of interferon (IFN)-α-based therapy in HDV. METHODS:We performed a systematic search on electronic databases including MEDLINE (1970 to January 2011), Web of Science, The Cochrane...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2306

    authors： Lamers MH,Kirgiz ÖÖ,Heidrich B,Wedemeyer H,Drenth JP

    更新日期：2012-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期：2007-01-01 00:00:00

  • In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.

    abstract：BACKGROUND:Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we inves...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3180

    authors： Baz M,Goyette N,Griffin BD,Kobinger GP,Boivin G

    更新日期：2017-01-01 00:00:00

  • Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

    abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：10.3851/IMP1780

    authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

    更新日期：2011-01-01 00:00:00

  • Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

    abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2570

    authors： Flores MV,Corbau RG,Guionaud S

    更新日期：2013-01-01 00:00:00

  • Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.

    abstract：BACKGROUND:Protease inhibitors (PI) have relatively low penetration into the genital tract, raising concerns about the potential for genital HIV RNA shedding in patients taking PI-based regimens, particularly PI monotherapy (PI-mono). METHODS:We measured HIV RNA and PI drug concentrations in samples of semen, cervico-...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3340

    authors： Arenas-Pinto A,Stöhr W,Khoo S,Clarke A,Beeching N,Warwick Z,Lee V,Else L,Wiggins R,Ferns B,Nastouli E,Dunn D,Lacey CJ,Paton NI,Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Genital Secretion sub-study T

    更新日期：2020-01-01 00:00:00

  • Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing.

    abstract：:In 1998 it seems reasonable and widely accepted that all human immunodeficiency virus type 1 (HIV-1)-infected patients willing to be treated may benefit from receiving antiretroviral therapy. Only those with undetectable plasma HIV-1 RNA, normal CD4 lymphocyte counts and lack of markers of immunological system activat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Gatell JM

    更新日期：1998-01-01 00:00:00

  • A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

    abstract：BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

    更新日期：2007-01-01 00:00:00

  • Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?

    abstract：:Phanuphak et al. compared three strategies for first-line antiretroviral therapy in 150 Thai patients: initiating therapy with zidovudine (AZT), tenofovir disoproxil fumarate (TDF), or a 24-week lead-in phase with stavudine (d4T) followed by a switch to AZT. Those taking d4T had higher haemoglobin levels and CD4(+) T-...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2498

    authors： Gallant JE

    更新日期：2012-01-01 00:00:00

  • The potential role of HCV core antigen testing in diagnosing HCV infection.

    abstract：:The potential uses of serological tests that detect HCV core antigens in biological fluids are highlighted. The most common serological tests utilized to detect exposure to HCV rely on the detection of antibodies to HCV. However, these tests cannot distinguish between individuals who have resolved their infection and ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2463

    authors： Dawson GJ

    更新日期：2012-01-01 00:00:00

  • Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

    abstract：BACKGROUND/AIMS:We conducted a case-control study to investigate the efficacy of interferon-alpha (IFN-alpha) and ribavirin combination therapy for patients with chronic hepatitis C and B virus (HCV/HBV) coinfection and to elucidate the interaction of these two viruses. METHODS:Forty-two chronic HCV/HBV-coinfected pat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chuang WL,Dai CY,Chang WY,Lee LP,Lin ZY,Chen SC,Hsieh MY,Wang LY,Yu ML

    更新日期：2005-01-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract：BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP1931

    authors： Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期：2011-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract：BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期：2008-01-01 00:00:00

  • Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.

    abstract：BACKGROUND:Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the prox...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3373

    authors： Brunet L,Wyatt C,Hsu R,Mounzer K,Fusco J,Fusco G

    更新日期：2020-11-19 00:00:00